Dr. Jamieson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
101 Manning Dr
Chapel Hill, NC 27514Phone+1 984-974-0000Fax+1 919-966-7772- Is this information wrong?
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 1995 - 1999
Advocate Health Care/Advocate Illinois Masonic Medical CenterResidency, Internal Medicine, 1992 - 1995
Wroclaw Medical UniversityClass of 1987
Certifications & Licensure
NC State Medical License 2012 - 2025
IA State Medical License 2008 - 2014
FL State Medical License 1999 - 2013
IL State Medical License 1992 - 1999- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Start of enrollment: 2006 Sep 01
- Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens Start of enrollment: 2006 Jul 01
- HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Start of enrollment: 2016 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsAnti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30lymphoma: a phase 1 study.Natalie S Grover, George Hucks, Marcie L Riches, Anastasia Ivanova, Dominic T Moore, Thomas C Shea, Mary Beth Seegars, Paul M Armistead, Kimberly A Kasow, Anne W Beave...> ;The Lancet. Haematology. 2024 Mar 28
- 6 citationsThree-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow D...Bronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, Brent R Logan, Farhad Khimani, Brian C Shaffer, Nirav N Shah, Alisha Mussetter, Xiao-Ying Tang, John M M...> ;Transplantation and Cellular Therapy. 2023 Mar 1
- Phase Ib trial of lenalidomide as post-remission therapy for older adults with acute myeloid leukemia: Safety and longitudinal assessment of geriatric functional domains.Justin D Woods, Joshua F Zeidner, Hendrik W Van Deventer, Katarzyna Jamieson, Melissa Matson, Jack Zhang, William Pulley, Tucker Brenizer, Hyman Muss, Kirsten A Nyrop,...> ;Journal of Geriatric Oncology. 2022 May 1
- Join now to see all
Abstracts/Posters
- Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...Katarzyna Jamieson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AMLKatarzyna Jamieson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Hospital Affiliations
University of North Carolina HospitalsChapel Hill, North Carolina
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
